Suggested remit - To appraise the clinical and cost effectiveness of rivaroxaban within its marketing authorisation for treating heart failure in people with coronary heart disease
Status Awaiting development
Decision None selected
Process TA
ID number 1462

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
27 September 2018 - 25 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
09 October 2018 The company that manufacture rivaroxaban has advised NICE that they are no longer pursuing a licence in the UK for this product for this indication at this time. In light of this information the Institute will not be progressing with the scoping exercise. Consequently, the consultation on the draft scope has now been closed early. Thank you for any comments that have already been received. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on

For further information on our processes and methods, please see our CHTE processes and methods manual